Drug intelligence / Profile preview

sublingual insulin

Development stage: Preclinical
Lead developer: Biolingus
Modality: Peptides
Administration: Sublingual

Overview

Sublingual insulin is a preclinical-stage peptide therapeutic being developed by BioLingus for the treatment of diabetes. The drug utilizes a proprietary sublingual delivery platform designed to stabilize the insulin peptide and facilitate its absorption through the mucous membranes under the tongue. By bypassing the gastrointestinal tract and avoiding the need for subcutaneous injections, this formulation aims to improve patient compliance and provide a non-invasive alternative for glycemic control. It acts as an agonist at the insulin receptor, stimulating cellular glucose uptake and lowering blood sugar levels.

Other names: BioLingus sublingual insulin

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on sublingual insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sublingual insulin.

Explore the full profile